Galapagos files registration statement in the United States for a proposed global offering
15 Abril 2015 - 4:00PM
Mechelen,
Belgium; 15 April 2015 - Galapagos NV (Euronext: GLPG) announced
today that it filed a Registration Statement on Form F-1 with the
U.S. Securities and Exchange Commission for a proposed global
offering of ordinary shares, including ordinary shares in the form
of American Depositary Shares ("ADSs").
Galapagos' ordinary shares are
currently listed on Euronext Amsterdam and Euronext Brussels.
Application has been made to list the ADSs to be offered in
the global offering on the NASDAQ Stock Market in the United States
under the symbol "GLPG." Within the framework of the
contemplated transaction, Galapagos expects to offer ordinary
shares in Europe and countries outside of the United States and
Canada in a concurrent private placement. Investors other
than qualified investors under applicable law will not be eligible
to participate in this possible private placement.
Morgan Stanley, Credit Suisse, and
Cowen and Company are acting as joint book-running managers, and
Nomura and Bryan, Garnier & Co. are acting as co-managers, for
the proposed global offering.
A registration statement relating
to these securities has been filed with the U.S. Securities and
Exchange Commission but has not yet become effective. The
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes
effective.
The securities referred to in this
release are to be offered only by means of a prospectus. A
copy of the preliminary prospectus, when available, can be obtained
from Morgan Stanley& Co. LLC, 180 Varick Street, 2nd Floor, New
York, NY 10014, United States, Attention: Prospectus Department;
Credit Suisse Securities (USA) LLC, One Madison Avenue, New York,
NY 10010, United States, Attention: Prospectus Department, or by
telephone at +1 (800) 221-1037, or by email at
newyork.prospectus@credit-suisse.com; or Cowen and Company, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY, 11717, United States, Attn.: Prospectus Department or by
calling +1 (631) 274 2806.
This press release does not
constitute an offer to sell nor a solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a collaboration agreement for the development and
commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. AbbVie and Galapagos also signed a
collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR
gene. Potentiator GLPG1837 is currently in a Phase 1 trial,
and corrector GLPG2222 is at the pre-clinical candidate
stage. GLPG1205, a first-in-class inhibitor of GPR84 and
fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of
autotaxin, has shown favorable safety in a Phase 1 trial and is
expected to enter Phase 2 in idiopathic pulmonary fibrosis.
The Galapagos Group, including fee-for-service subsidiary Fidelta,
has approximately 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and
Croatia.
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking
statements
This release may contain forward-looking
statements regarding the commercial potential of our product
candidates generally, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," "continues," "we believe," "we
intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements.
Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1911616
Galapagos (LSE:GLPG)
Gráfica de Acción Histórica
De Oct 2024 a Oct 2024
Galapagos (LSE:GLPG)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024